Logo

Sequenom, Provid Pharma to Co-Develop Small-Molecule Tx

Apr 10, 2002

NEW YORK, April 10 - Sequenom and Provid Pharmaceuticals today said they plan to co-develop small-molecule therapeutics based on cardiovascular targets discovered by Sequenom.
 
Terms of the deal call for privately held Provid to receive an equity investment and research funding, and to be eligible for milestones and royalties on any products that may arise.

Financial details of the collaboration were not disclosed.

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.